We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LUV:NYSESouthwest Airlines Company Analysis

Data as of 2026-04-16 - not real-time

$41.70

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Southwest Airlines is trading at $41.7, which sits below the DCF‑derived fair value of $43.39, implying roughly a 6% upside potential. The stock’s trailing P/E of 52.8 is well above the airline industry average of 30.9, suggesting current earnings appear stretched, yet the forward P/E of 9.2 points to strong earnings growth expectations. A beta of 1.42 and a 30‑day volatility of 54% highlight a higher‑than‑average market risk profile, while the RSI of 53 and a bullish MACD histogram indicate neutral‑to‑slightly‑positive momentum. Dividend yield stands at 1.75% with a payout ratio of 91%, raising questions about dividend sustainability given negative free cash flow. Recent leadership announcements aim to enhance customer experience, and UBS maintained a Buy rating with a revised price target of $56, while Redburn raised its target to $35 despite a sell rating. Analyst consensus remains a “hold,” and the median price target of $45 aligns with the modest upside suggested by the valuation model.
The technical landscape shows the price hovering between a support of $35.73 and resistance of $43.43, with decreasing volume that may limit short‑term rally strength. The company’s revenue growth of 7.4% and a forward EPS of $4.51 reinforce a medium‑term earnings upside narrative. However, a debt‑to‑equity ratio of 74.9% and negative free cash flow underscore liquidity concerns that temper long‑term optimism. Overall, the stock presents a blend of value and growth attributes, with modest upside, elevated risk, and dividend sustainability issues.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with limited upside
  • High volatility and beta increase short‑term risk
  • Decreasing volume may constrain price moves

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings growth implied by low forward P/E
  • DCF fair value indicates modest upside
  • Analyst upgrades and price‑target revisions supporting upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong brand and loyalty program underpin demand recovery
  • Elevated debt levels and negative free cash flow limit margin expansion
  • Dividend yield attractive but sustainability concerns remain

Key Metrics & Analysis

Financial Health

Revenue Growth7.40%
Profit Margin1.57%
P/E Ratio52.8
ROE4.81%
ROA0.95%
Debt/Equity74.94
P/B Ratio2.7
Op. Cash Flow$1.8B
Free Cash Flow$-683875008
Industry P/E30.9

Technical Analysis

TrendNeutral
RSI53.8
Support$35.73
Resistance$43.43
MA 20$39.30
MA 50$44.75
MA 200$37.55
MACDBullish
VolumeDecreasing
Fear & Greed Index88.98

Valuation

Fair Value$43.39
Target Price$44.21
Upside/Downside6.02%
GradeFair
TypeBlend
Dividend Yield1.75%

Risk Assessment

Beta1.42
Volatility54.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.